The Medical Letter on Drugs and Therapeutics
FROM
ISSUE 1571
ISSUE 1571
May 6, 2019
Siponimod (Mayzent) - A New Drug for Multiple Sclerosis
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
May 6, 2019 (Issue: 1571)
The FDA has approved siponimod (Mayzent –
Novartis), a sphingosine 1-phosphate (S1P) receptor
modulator, for oral treatment of adults with relapsing
forms of multiple sclerosis (MS), including clinically
isolated syndrome (initial neurological episode),
relapsing-remitting disease, and active secondary
progressive MS (SPMS). Siponimod is the second
S1P receptor modulator to be approved in the US;
fingolimod (Gilenya), which is approved for oral
treatment of relapsing forms of MS in patients ≥10
years old, was the first. The purine antimetabolite
cladribine (Mavenclad) was also recently approved
for oral treatment of relapsing forms of MS and will be
reviewed in a future issue.
... more
- Drugs for multiple sclerosis. Med Lett Drugs Ther 2016; 58:71.
- Ocrelizumab (Ocrevus) for MS. Med Lett Drugs Ther 2017; 59:98.
- V Hamidi et al. A multiple treatment comparison of eleven disease-modifying drugs for multiple sclerosis. J Clin Med Res 2018; 10:88.
- BZ Chaudhry et al. Sphingosine 1-phosphate receptor modulators for the treatment of multiple sclerosis. Neurotherapeutics 2017; 14:859.
- N Behrangi et al. Mechanism of siponimod: anti-inflammatory and neuroprotective mode of action. Cells 2019; 8:24.
- L Kappos et al. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. Lancet 2018; 391:1263.
- Inhibitors and inducers of CYP enzymes and P-glycoprotein. Med Lett Drugs Ther 2017 September 18 (epub). Available at: medicalletter.org/downloads/CYP_PGP_Tables.pdf.

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this article? Gain access below.
Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App for iOS, Android, and Kindle Fire
- FREE online per issue CME/CE
Purchase this article:
Title: Siponimod (Mayzent) - A New Drug for Multiple Sclerosis
Article code: 1571c
Electronic, downloadable article - $45
Article code: 1571c
Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian